title: Pretargeted radioimmunotherapy: clinically more efficient than conventional radioimmunotherapy?
authors.forename: Caroline
authors.initials: C
authors.lastname: Rousseau
authors.forename: Françoise
authors.initials: F
authors.lastname: Kraeber-Bodéré
authors.forename: Jacques
authors.initials: J
authors.lastname: Barbet
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Chatal
mesh_terms: D000818:Animals; D018033:Antibodies, Bispecific / Q000493:pharmacokinetics*; D006573:Heterocyclic Compounds, 1-Ring / Q000493:pharmacokinetics*; D006801:Humans; D008297:Male; D009842:Oligopeptides / Q000493:pharmacokinetics*; D049268:Positron-Emission Tomography; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging*; D016499:Radioimmunotherapy; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*
chemical_list: D018033:Antibodies, Bispecific; C515662:DOTA-tyrosyl-lysyl(histaminyl-succinyl-glycyl)-glutamyl-lysyl(histaminyl-succinyl-glycyl)amide; D006573:Heterocyclic Compounds, 1-Ring; D009842:Oligopeptides; D019275:Radiopharmaceuticals